<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647773</url>
  </required_header>
  <id_info>
    <org_study_id>HSK16149-201/301</org_study_id>
    <nct_id>NCT04647773</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Pregabalin Capsule-Controlled, 13-Week, Adaptive-design Phase 2/3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Diabetic Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the efficacy and safety of HSK16149 capsules in Chinese diabetic peripheral&#xD;
      neuropathic pain (DPNP) following 13 weeks treatment in comparison to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2020</start_date>
  <completion_date type="Anticipated">November 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 9, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the change from baseline in Average Daily Pain Score（ADPS） between HSK16149 and placebo at week 5.</measure>
    <time_frame>Baseline and week 5</time_frame>
    <description>The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the change from baseline in Average Daily Pain Score （ADPS） between HSK16149 and placebo at week 13.</measure>
    <time_frame>Baseline and week 13</time_frame>
    <description>The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the response rate between HSK16149 and placebo at week 5 (Proportion of subjects whose ADPS decreased by ≥30% and ≥50% from baseline ).</measure>
    <time_frame>Baseline and week 5</time_frame>
    <description>Ratio of Participants Responding to Treatment, as Measured by Average Daily Pain Score (ADPS) Reduction from Baseline. The ADPS is used to determine categorical response rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE, laboratory tests, physical and neurological examination, vital signs and 12-lead ECG to evaluate the safety of HSK16149 in 5 weeks post treatment.</measure>
    <time_frame>From week 1 to week 5</time_frame>
    <description>Number and severity of AEs, clinical laboratory abnormalities, physical examinations, 12-lead electrocardiograms (ECGs), and vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the response rate between HSK16149 and placebo at week 13 (Proportion of subjects whose ADPS decreased by ≥30% and ≥50% from baseline ).</measure>
    <time_frame>Baseline and week 13</time_frame>
    <description>Ratio of Participants Responding to Treatment, as Measured by Average Daily Pain Score (ADPS) Reduction from Baseline. The ADPS is used to determine categorical response rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change from baseline in ADPS between HSK16149 and placebo at week 1 to 13.</measure>
    <time_frame>From week 1 to week 13</time_frame>
    <description>The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change from baseline in Visual Analog Scale （VAS） between HSK16149 and placebo at week 13.</measure>
    <time_frame>Baseline and week 13</time_frame>
    <description>VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change from baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) between HSK16149 and placebo at week 13.</measure>
    <time_frame>Baseline and week 13</time_frame>
    <description>Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score:&#xD;
Part 1 - fifteen descriptors of pain intensity, on a scale of 0 (none) to 3 (severe)&#xD;
Part 2 - a visual analog scale (VAS), in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain&#xD;
Part 3 - a Present Pain Intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the Patient Global Impression of Change（PGIC） between HSK16149 and placebo at week 13.</measure>
    <time_frame>Week 13</time_frame>
    <description>Patient global impression of change (PGIC) on a 7-point categorical scale, where 1 = very much improved and 7 = very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change from baseline in Average Daily Sleep Interference score (ADSIS) between HSK16149 and placebo at week 13.</measure>
    <time_frame>Baseline and week 13</time_frame>
    <description>The sleep interference scores on a scale of 0-10, where 0 = pain did not interfere with sleep to 10 = pain completely interfered with sleep. The weekly ADSIS is based on participants daily sleep interference scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change from baseline in EuroQol-5-Domain-5-Level health questionnaire (EQ-5D-5L) between HSK16149 and placebo at week 13.</measure>
    <time_frame>Baseline and week 13</time_frame>
    <description>The change from baseline in total EuroQol-5-Domain-5-Level health questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE, laboratory tests, physical and neurological examination, vital signs and 12-lead ECG to evaluate the safety of HSK16149 during the trial.</measure>
    <time_frame>From week 1 to week 14</time_frame>
    <description>Number and severity of AEs, clinical laboratory abnormalities, physical examinations, 12-lead electrocardiograms (ECGs), and vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) characteristics of HSK16149 capsules in Chinese patients with diabetic peripheral neuropathic pain.</measure>
    <time_frame>Week 1,week 5,week 11,week 13</time_frame>
    <description>Pharmacokinetics will be determined by measuring serum concentration of HSK16149.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">687</enrollment>
  <condition>Diabetic Peripheral Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>HSK16149 20mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK16149 40mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK16149 60mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK16149 80mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin 150mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK16149 20mg BID</intervention_name>
    <description>HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.</description>
    <arm_group_label>HSK16149 20mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK16149 40mg BID</intervention_name>
    <description>HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.</description>
    <arm_group_label>HSK16149 40mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK16149 60mg BID</intervention_name>
    <description>HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.</description>
    <arm_group_label>HSK16149 60mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK16149 80mg BID</intervention_name>
    <description>HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.</description>
    <arm_group_label>HSK16149 80mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150mg BID</intervention_name>
    <description>Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.</description>
    <arm_group_label>Pregabalin 150mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo BID</intervention_name>
    <description>Placebo, orally twice a day, treatment period; 13-weeks fixed dose.</description>
    <arm_group_label>Placebo BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent;&#xD;
&#xD;
          2. Males or females aged 18-75 years of age inclusive;&#xD;
&#xD;
          3. Diagnosis of diabetic peripheral neuropathic pain (DPNP) and diabetic peripheral&#xD;
             neuropathy (DPN) pain ≥ 6 months;&#xD;
&#xD;
          4. HbA1c ≤ 9.0% at screening and on a stable antidiabetic medication regimen for at least&#xD;
             30 days prior to screening;&#xD;
&#xD;
          5. At Screening, pain scale (VAS) of ≥40 mm and &lt;90 mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Peripheral neuropathy or pain unrelated to DPN that may confuse the assessment of&#xD;
             DPNP.&#xD;
&#xD;
          2. Skin conditions in the area affected by neurupathy that could alter sensation.&#xD;
&#xD;
          3. Chronic systemic diseases that may affect subjects' participation in the study.&#xD;
&#xD;
          4. Severe hematologic, hepatic or renal dysfunction, the subject will be excluded if:&#xD;
&#xD;
               1. Neutrophils &lt; 1.5 × 10^9/L, or platelet &lt; 90 × 10^9/L, or hemoglobin &lt; 100 g/L,&#xD;
                  or&#xD;
&#xD;
               2. AST/ALT &gt; 2.5 × upper limit of normal (ULN), or TBIL &gt; 1.5 × ULN, or&#xD;
&#xD;
               3. Estimation of glomerular filtration rate (eGFR) &lt; 60 mL/min / 1.73 m^2, or&#xD;
&#xD;
               4. Creatine kinase &gt; 2.0 × ULN.&#xD;
&#xD;
          5. History of substance abuse or alcohol abuse.&#xD;
&#xD;
          6. Acute complications of diabetes in the 6 months prior to screening.&#xD;
&#xD;
          7. Any active infections at screening.&#xD;
&#xD;
          8. HBsAg or HCV Ab positive, or HIV Ab positive, or serum TP Ab positive.&#xD;
&#xD;
          9. Inability or unwillingness to discontinue any other prohibited concomitant medications&#xD;
             (see Section 6.3).&#xD;
&#xD;
         10. Failure to response to previous treatment with pregabalin at doses ≥ 300 mg/d or&#xD;
             gabapentin at doses ≥ 1200 mg/d for treatment of DPNP.&#xD;
&#xD;
         11. History of allergic or medically significant adverse reaction to investigational&#xD;
             products or their excipients, acetaminophen or related compounds.&#xD;
&#xD;
         12. History of suicidal behavior or attempted suicide.&#xD;
&#xD;
         13. Pregnant or preparing for pregnancy or breastfeeding during the study period, or&#xD;
             subjects were not willing to use reliable contraceptives methods from the date of ICF&#xD;
             signature until 28 days after the last trial drug administration, or planning to use&#xD;
             progesterone contraceptives during this period.&#xD;
&#xD;
         14. Participated in another clinical study within 30 days prior to screening.&#xD;
&#xD;
         15. Other conditions of the subjects who are unlikely to comply with the protocol.&#xD;
&#xD;
         16. Could potentially affect a subject's safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fangqiong Li</last_name>
    <phone>+8602867258840</phone>
    <email>lifangq@haisco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaohui Guo, M.D.</last_name>
      <phone>13601337277</phone>
      <email>guoxh@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

